Lung Cancer
Volume 69, Issue 1 , Pages 19-25 , July 2010

CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians

  • Ping Zhan

      Affiliations

    • The First Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing 210029, China
    • ,
  • Jing Wang

      Affiliations

    • Department of Hematology, The Affiliated DrumTower Hospital of Nanjing University School of Medicine, Nanjing, China
    • ,
  • Yu Zhang

      Affiliations

    • The First Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing 210029, China
    • ,
  • Li-Xin Qiu

      Affiliations

    • Department of Medical Oncology, Cancer Hospital, Shanghai Medical College, Fudan University, Shanghai, China
    • ,
  • Su-feng Zhao

      Affiliations

    • Department of Oral and Maxillofacial Surgery, The Affiliated Stomatology Hospital, Nanjing University School of Medicine, Nanjing, China
    • ,
  • Qian Qian

      Affiliations

    • Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, China
    • ,
  • Shu-Zhen Wei

      Affiliations

    • Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, China
    • ,
  • Li-Ke Yu

      Affiliations

    • The First Department of Respiratory Medicine, Nanjing Chest Hospital, 215 Guangzhou Road, Nanjing 210029, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 25 8372 8558; fax: +86 25 8372 8558.
    • ,
  • Yong Song

      Affiliations

    • Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 25 8086 3591; fax: +86 25 8086 3591.

Received 11 June 2009 ,Revised 27 August 2009 ,Accepted 1 September 2009.

References 

  1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123:21–49
  2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594
  3. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245–2251
  4. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, et al. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control. 2003;14:339–346
  5. Carlsten C, Sagoo GS, Frodsham AJ, Burke W, Higgins JP. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. Am J Epidemiol. 2008;167:759–774
  6. Raimondi S, Paracchini V, Autrup H. Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol. 2006;164:1027–1042
  7. Yamazaki H, Inui Y, Yun C, Guengerich FP, Shimada T. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis. 1992;13:1789–1794
  8. Bellec G, Dreano Y, Lozach P, Menez JF, Berthou F. Cytochrome P450 metabolic dealkylation of nine N-nitroso-dialkylamines by human liver microsomes. Carcinogenesis. 1996;17:2029–2034
  9. Hoffmann D, Hecht SS. Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions. Cancer Res. 1985;45:935–944
  10. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988;9:875–884
  11. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, et al. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res. 1991;82:254–256
  12. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129
  13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748
  14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  15. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technol Bull. 1999;8:15–17
  16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  17. Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, et al. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev. 1998;7:13–18
  18. Gu YF, Zhang SC, Lai BT, Wang H, Zhan XP. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility. Chin J Lung Cancer. 2004;7:112–117[in Chinese]
  19. Wang BG, Chen SD, Chen Y, Zhou WP, Zeng M, Li ZB. Case control study on impact of cytochrome P450 2E1 and 1A1 gene polymorphisms on the risk of lung cancer. Chin J Cancer Prev Treat. 2004;11:681–702[in Chinese]
  20. Li DR, Zhou QH, Yuan TZ, Guo ZL, Zhu W, Wang YP, et al. Study on the association between genetic polymorphism of CYP2E1, GSTM1 and susceptibility of lung cancer. Chin J Lung Cancer. 2005;8:14–19[in Chinese]
  21. Eom SY, Zhang YW, Kim SH, Choe KH, Lee KY, Park JD, et al. Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. Cancer Causes Control. 2009;20:137–145
  22. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–1169
  23. Li D, Zhou QH, Guo Z, Yuan TZ, Zhu W, Wang YP, et al. Association between genetic polymorphisms of CYP2E1 and lung cancer susceptibility: a case control study. Acta Acdaemiae Medicine Militrais Tertiae. 2008;30:1231–1234[in Chinese]
  24. Minegishi Y, Tsukino H, Muto M, Goto K, Gemma A, Tsugane S, et al. Susceptibility to lung cancer and genetic polymorphisms in the alcohol metabolite-related enzymes alcohol dehydrogenase 3, aldehyde dehydrogenase 2, and cytochrome P450 2E1 in the Japanese population. Cancer. 2007;110:353–362
  25. Gu YF, Zhang ZD, Zhang SC, Zheng SH, Jia HY, Gu SX. Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility. Zhonghua Yi Xue Za Zhi. 2007;87:3064–3068[in Chinese]
  26. Ye WY, Chen SD, Chen Q, Zhang DQ, Cai XL. Association of CYP2E1 polymorphism and serum selenium level with risk of human lung cancer. Tumor. 2006;26:450–452[in Chinese]
  27. Wang DQ, Chen SD, Wang BG, Zhou WP. A case-control study on the impact of cytochrome P450 2E1 and 1A1 gene polymorphisms on the risk of lung cancer of the Han nationality in Guangzhou district. Chin J Lung Cancer. 2006;9:497–501[in Chinese]
  28. Lee KM, Kang D, Lee SJ, Park SK, Lee KH, Choi JY, et al. Interactive effect of genetic polymorphism of glutathione S-transferase M1 and smoking on squamous cell lung cancer risk in Korea. Oncol Rep. 2006;16:1035–1039
  29. Liang GY, Pu YP, Yin LH. Studies of the genes related to lung cancer susceptibility in Nanjing Han population, China. Yi Chuan. 2004;26:584–588[in Chinese]
  30. Wang J, Deng Y, Li L, Kuriki K, Ding J, Pan X, et al. Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci. 2003;94:448–452
  31. Shi Y, Zhou X, Zhou Y, Ren S. Analysis of CYP2E1, GSTM1 genetic polymorphisms in relation to human lung cancer and esophageal carcinoma [in Chinese]. J Huazhong Univ Sci Technol [Health Sci]. 2002;3:14–17
  32. Quiñones L, Lucas D, Godoy J, Cáceres D, Berthou F, Varela N, et al. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. 2001;174:35–44
  33. Li Z, Tan W, Shao K. Susceptibility to lung cancer in Chinese is associated with genetic polymorphism in cytochrome P4502E1. Zhonghua Zhong Liu Za Zhi. 2000;22:5–7[in Chinese]
  34. Huang YH, Wang QS, Zhu LZ, Zhang Y. Relationship between Cytochrome P450 2E1 genetic polymorphism and lung cancer in Chinese Han subjects. Chin J Clin Pharmacol. 2000;16:350–352[in Chinese]
  35. Wang SL, Lee H, Chen KW, Tsai KJ, Chen CY, Lin P. Cytochrome P4502E1 genetic polymorphisms and lung cancer in a Taiwanese population. Lung Cancer. 1999;26:27–34
  36. Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res. 1998;58:4858–4863
  37. Qu YH, Shi YB, Zhong LJ, Sun L, Sun XW, Chen JR, et al. Cytochrome P450 2E1 genetic polymorphism and non-smoking female lung cancer risk. Carcinogenesis Teratogenesis Mutagenesis. 1998;10:355–358[in Chinese]
  38. Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, et al. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis. 1997;18:967–973
  39. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, et al. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res. 1997;17:583–587
  40. Watanabe J, Yang JP, Eguchi H, Hayashi S, Imai K, Nakachi K, et al. An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn J Cancer Res. 1995;86:245–248
  41. Persson I, Johansson I, Bergling H, Dahl ML, Seidegård J, Rylander R, et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett. 1993;319:207–211
  42. Burg JR, Gist GL. The national exposure registry: procedures for establishing a registry of persons environmental exposed to hazardous substances. Toxicol Ind Health. 1995;11:231–248
  43. Shen X, Eang G, Huang Y, Xiang L, Wang X. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer (Suppl.). 1996;14:S107–S112
  44. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev. 1994;26:165–183
  45. Windmill KF, McKinnon RA, Zhu X, Gaedigk , Grant DM, McManus ME. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res. 1997;376:153–160
  46. Oyama T, Sugio K, Uramoto H, Kawamoto T, Kagawa N, Nadaf S, et al. Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci. 2007;12:2299–2308
  47. Hirschhorn JN, Lohmueller K, Byrne E. A comprehensive reviewof genetic association studies. Genet Med. 2002;4:45–61
  48. Sato S, Nakamura Y, Tsuchiya E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 1994;54:5652–5655
  49. Hayashi SI, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991;110:559–565
  50. Lucas D, Menez C, Girre C, Berthou F, Bodenez P, Joannet I, et al. Cytochrome P4502E1 genotype and chloroxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics. 1995;5:298–304
  51. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther. 1996;279:4–11
  52. Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ, et al. Family history and risk of fatal prostate cancer. Epidemiology. 1997;8:653–659

PII: S0169-5002(09)00485-1

doi: 10.1016/j.lungcan.2009.09.001

Lung Cancer
Volume 69, Issue 1 , Pages 19-25 , July 2010

Article Tools

* Image Usage & Resolution